<DOC>
	<DOCNO>NCT01898039</DOCNO>
	<brief_summary>This study design patient malignant melanoma , follow tumor removal , free disease , minor residual disease , high risk disease recurrence . These patient treat A2/4-1BBL melanoma vaccine , compatible melanoma cell line engineer express molecule term 4-1BBL , enhances chance cell line recognize patient 's immune system , induce stimulation . The hypothesis drive study state immune response cell line also effective residual tumor may still present body .</brief_summary>
	<brief_title>Modified Melanoma Vaccine High Risk Low Residual Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>1 . Patients include protocol must carry one follow tissue type allele : HLAA2 , A24 , A33 , B35 , B49 , CW04/12 ( 04/08 ) . We estimate 50 % melanoma patient eligible . 2 . Cutaneous malignant melanoma AJCC stage IIb ( &gt; 4 mm ) IIc ( ulcerated melanoma &gt; 4mm ) . 3 . Metastatic melanoma AJCC stage III ( nodal involvement , N13a , b ) postsurgical removal lymph node . 4 . Metastatic melanoma AJCC stage IV , completely resect . 5 . Nonresectable metastatic melanoma low burden disease normal LDH undergone least two treatment line , include chemotherapy ( DTIC , temodal , taxanes , platinum compound ) , antiCTLA4 ( ipilimumab ) BRAF inhibitor harbor V600E BRAF mutation tumor . 6 . Non cutaneous malignant melanoma respective stage include uveal mucosal melanoma . 7 . Melanoma either mutant wildtype BRAF . 8 . Karnofsky performance status &gt; 80 ( Normal activity effort ) . 9 . No active cardiorespiratory disease . 10 . Not pregnant nursing . Women must take contraceptive treatment period.Hematocrit &gt; 25 % WBC &gt; 3000 . 11 . Informed consent patient . 1 . Administration cytotoxic drug extensive radiotherapy le 28 day prior protocol administration . 2 . Active brain metastasis require corticosteroid . 3 . Concurrent malignancy ( skin cancer , carcinoma situ cervix early stage prostate cancer ) . 4 . Active serious infection . 5 . Allergy penicillin . 6 . Patient 's withdraw study stage . 7 . HIV chronic hepatitis B C carrier</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>malignant melanoma</keyword>
	<keyword>vaccine</keyword>
	<keyword>cell line</keyword>
	<keyword>high risk</keyword>
	<keyword>residual disease</keyword>
</DOC>